Results 71 to 80 of about 3,580,419 (303)

Associations Between Serum Soluble Toll-like Receptors 4 and 9 and Breast Cancer in Egyptian Patients

Cancer Control, 2023
Background Toll-like receptors (TLRs) play an important role in regulation of immune cells and are vital in tumorigenesis due to its crucial role in inflammatory microenvironment regulation, as they promote the synthesis and release of inflammatory ...
Inas Moaz, Fayrouz A. Fouad, Hossam Elmasry, Gehad Tarek, Aya Elzoheiry, Manar Elgamal, Randa Ibrahim, Yasmin Hisham, Gehan Safwat, Mahmoud M. Kamel, Heba M. El-Batal, Merhan Fouda   +11 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Metastatic Breast Cancer and Hormonal Receptor Status among a Group of Women in Sub Saharan Africa

The Annals of African Surgery, 2018
Background: Breast cancer is the third commonest cancer in women in Uganda. The majority of breast cancer patients in Uganda present with advanced disease. Many studies show that metastatic lesions frequently lodge in bones, lung and liver.
Nabawanuka A, Galukande M, Nalwoga H, Gakwaya A   +3 more
doaj  

IP-10 (CXCL10) Can Trigger Emergence of Dormant Breast Cancer Cells in a Metastatic Liver Microenvironment

Frontiers in Oncology, 2021
Metastatic breast cancer remains a largely incurable and fatal disease with liver involvement bearing the worst prognosis. The danger is compounded by a subset of disseminated tumor cells that may lie dormant for years to decades before re-emerging as ...
Amanda M. Clark, Amanda M. Clark, Amanda M. Clark, Haley L. Heusey, Haley L. Heusey, Linda G. Griffith, Douglas. A. Lauffenburger, Alan Wells, Alan Wells, Alan Wells, Alan Wells   +10 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Metastatic Breast Cancer to the Common Bile Duct Presenting as Obstructive Jaundice

Case Reports in Gastroenterology, 2015
Metastatic breast cancer is typically identified in the bones, lymph nodes, lungs and liver. Rarely does metastatic breast cancer involve the common bile duct (CBD) without direct extension from liver metastasis into the CBD. We present a woman diagnosed
Justin Cochrane, Greg Schlepp
doaj   +1 more source

The role of von Willebrand factor in breast cancer metastasis

Translational Oncology, 2021
Breast cancer is the most common female cancer globally, with approximately 12% of patients eventually developing metastatic disease. Critically, limited effective treatment options exist for metastatic breast cancer. Recently, von Willebrand factor (VWF)
Chia Yin Goh, Sean Patmore, Albert Smolenski, Jane Howard, Shane Evans, Jamie O'Sullivan, Amanda McCann   +6 more
doaj   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.

, 2007
Association studies in large series of breast cancer patients can be used to identify single-nucleotide polymorphisms (SNP) contributing to breast cancer susceptibility.
Pharoah, Paul DP, Hogervorst, Frans BL, Dunning, Alison M, Nevanlinna, Heli A, Blomqvist, Carl,, Tommiska, Johanna, Healey, Catherine S, Pharoah, Paul D P, Tollenaar, Rob A E M, Reincke, Scarlett, Peto, Julian, Blomqvist, Carl, Van't Veer, Laura J, Johnson, Nichola, Fletcher, Olivia, Tollenaar, Rob AEM, Broeks, Annegien, Schmidt, Marjanka K, Braaf, Linde M, Hogervorst, Frans B L, Breast Cancer Association Consortium, Easton, Douglas F, Dörk, Thilo   +22 more
core   +1 more source

Metastatic Breast Cancer and Hormonal Receptor Status among a Group of Women in Sub Saharan Africa

The Annals of African Surgery, 2013
Background: Breast cancer is the third commonest cancer in women in Uganda. The majority of breast cancer patients in Uganda present with advanced disease. Many studies show that metastatic lesions frequently lodge in bones, lung and liver.
Nabawanuka A, Galukande M, Nalwoga H, Gakwaya A   +3 more
doaj